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Abstract: Patients with Lewy body disease (LBD) frequently experience visual hallucinations (VH),
well-formed images perceived without the presence of real stimuli. The structural and functional
brain mechanisms underlying VH in LBD are still unclear. The present review summarises the current
literature on the neural correlates of VH in LBD, namely Parkinson’s disease (PD), and dementia
with Lewy bodies (DLB). Following a systematic literature search, 56 neuroimaging studies of VH
in PD and DLB were critically reviewed and evaluated for quality assessment. The main structural
neuroimaging results on VH in LBD revealed grey matter loss in frontal areas in patients with
dementia, and parietal and occipito-temporal regions in PD without dementia. Parietal and temporal
hypometabolism was also reported in hallucinating PD patients. Disrupted functional connectivity
was detected especially in the default mode network and fronto-parietal regions. However, evidence
on structural and functional connectivity is still limited and requires further investigation. The
current literature is in line with integrative models of VH suggesting a role of attention and perception
deficits in the development of VH. However, despite the close relationship between VH and cognitive
impairment, its associations with brain structure and function have been explored only by a limited
number of studies.
Keywords: visual hallucinations; Lewy body; Parkinson’s disease; Parkinson’s disease dementia;
dementia with Lewy bodies; MRI; fMRI; DTI; PET; SPECT
1. Introduction
The term Lewy body disease (LBD) refers to disorders characterised by the neural inclusion of
pathologic α-synuclein aggregates called Lewy bodies [1,2]. Clinical manifestations of Lewy body
pathology include dementia with Lewy bodies (DLB), Parkinson’s disease (PD), and Parkinson’s
disease dementia (PDD). These diseases share some clinical characteristics, including motor symptoms,
sleep disorders, cognitive impairment, and visual hallucinations (VH) [3]. VHs represent a common
symptom experienced by patients with LBD, and they are among the core features of the DLB
symptomatology [4]. Recurrent and complex VHs have been defined as repetitive and well-formed
images, which are perceived without the presence of real stimuli [5]. The most commonly reported
VHs consist of people, animals, and inanimate objects, which appear to have similar features between
clinical conditions, especially DLB and PD with dementia [5–7]. Early false sensations of presence are
also common, mainly in PD [7]. Patients with LBD may also experience illusions or misperceptions,
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which are defined as incorrect perceptions of real stimuli [5,8]. VHs seem to be more severe and
complex in LBD patients with cognitive impairment, which often present with lack of insight about
the unreal nature of their experience [7].
The presence of VHs is a strong predictor of Lewy body pathology at autopsy [9,10]. Lewy body
pathology associated with VHs was shown to affect temporal lobe areas predominantly, mainly the
amygdala [11–13]. The structural and functional brain correlates underlying this symptomatology
are, however, still not well understood. Moreover, it is not clear whether different diseases within
the LBD spectrum share common neural mechanisms associated with VH, or whether they differ
between conditions. Neuroimaging techniques represent valuable tools, which may help in detecting
in vivo biomarkers that specifically characterise patients with VHs in PD and DLB. This may help the
achievement of a more accurate understanding of the biological vulnerabilities leading to VHs, and
may help future prediction of patients who are likely to develop these disabling symptoms, leading to
the possible implementation of preventive treatments.
The aim of the present review was to summarise the current literature on structural and functional
brain abnormalities associated with VHs in LBD, namely PD and DLB. Specifically, findings from
structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), functional MRI (fMRI),
positron emission tomography (PET), and single photon emission computed tomography (SPECT)
studies were critically reviewed.
2. Materials and Methods
Articles were identified through a systematic literature search, which was carried out in January
2017 by using the PubMed and Web of Science databases with no time limit. The following key words
were used: “visual hallucinations”, “visual hallucination”, “Lewy body", "dementia with Lewy bodies”,
“Parkinson’s disease”, “magnetic resonance imaging”, “MRI”, “voxel-based morphometry” (VBM) and
“VBM”, “fMRI”, "resting-state", “diffusion tensor imaging”, “DTI”, “positron emission tomography”
and “PET”, and “single photon emission computed tomography” and “SPECT”. An additional manual
search of references was also undertaken. Studies were excluded according to the following exclusion
criteria: (1) pathologies other than DLB, PD, or PDD; (2) neuroimaging analysis not related to VH;
(3) patients with medication-induced VH; (4) studies not using MRI, fMRI, DTI, PET, SPECT; (5) PET
and studies not investigating glucose metabolism and regional cerebral blood flow; (6) MRI studies
using visual rating; (7) magnetic resonance spectroscopic imaging; (8) pharmacological studies; (9)
case studies (except for fMRI during VH); (10) review and theoretical articles; (11) non-English articles;
and (12) non-peer reviewed articles. The search strategy used followed the PRISMA guidelines [14].
The articles included were assessed for scientific suitability to the aim of the present review, by using a
set of 14 criteria adapted from Welton et al. [15], (these criteria are listed in Supplementary Materials
Table S1). Each article was rated from 0 to 14, assessing the scientific quality of its structural and
functional neuroimaging analyses related to VH only.
3. Results
The initial search retrieved 646 titles, among which 387 were duplicate publications, which were
excluded. Three studies were identified through manual search. A total number of 262 titles and
abstracts were assessed, of which 88 full-text articles were retrieved and screened for eligibility. The
final review included 56 studies investigating the structural and functional brain correlates of VH
in LBD by using structural and functional MRI, DTI, PET, and SPECT. A flow chart describing the
selection process of the studies included in the final review is shown in Figure 1 (adapted from
Moher et al. [14]).
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Figure 1. Flow chart describing the selection process of the studies included (adapted from
Moher et al. [14]). 1 Exclusion criteria: (1) pathologies other than dementia with Lewy bodies (DLB),
Parkinson’s disease (PD), or Parkinson’s disease dementia (PDD); (2) neuroimaging analysis not related
to visual h llucin tions (VH); (3) patients with medication-induced VH; (4) studies not using magnetic
resonance imaging (MRI), functional MRI (fMRI), diffusion tensor imaging (DTI), positron emission
tomography (PET), and single photon emis ion computed tomography (SPECT); (5) PET and SPECT
studies not investigating glucose metabolism and regional cerebral blood flow; (6) MRI studies using
visual rating; (7) magnetic resonance spectroscopic imaging; (8) pharmacological studies; (9) case
studies (except for fMRI during VH); (10) review and theoretical articles; (11) non-English articles; and
(12) non-peer reviewed articles.
Studies investigating VH in LBD using more than one approach or imaging technique were
included in more than one section of the review and the findings for each technique reported separately
in the relevant section. There were eight studies combining different techniques, specifically structural
and functional MRI [16,17]; structural MRI and PET [18,19]; structural MRI and DTI [20,21]; structural
MRI, DTI, and fMRI [22]; and fMRI and arterial spin labelling (ASL)-MRI [23]. Moreover, in two
structural MRI studies, different methods were used to investigate regional brain volumes [24,25].
Suitability assessment of the articles reviewed revealed that structural (mean = 7.92), and
functional (mean = 7.06) neuroimaging analyses related to VH were of comparable quality. Overall,
among the main limitations of the studies, we found lack of a priori hypotheses on VH (n = 27 studies),
sample sizes <15 participants per group (n = 39 studies), and absence of correlational analyses with
VH indices (n = 35 studies) and cognitive measures (n = 49 studies). Quality assessment of each study
can be found in supplementary Table S2.
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3.1. Structural Brain Imaging
The brain structural changes associated with VH in LBD, detected with MRI, were investigated by
24 studies. The findings are summarised according to the analytic approach used, namely VBM, other
methods to investigate brain morphology, namely regional volumes, shape, and cortical thickness; and
DTI. For each study, detailed demographic, clinical, and methodological information—and imaging
results related to VH—are reported in Appendix A (Table A1).
3.1.1. Voxel-Based Morphometry
A total of 12 VBM studies were identified. Ten studies focused on regional volumetric brain
differences between LBD patients with and without VH, including nine studies which used whole
brain analyses [21,24–31], and three voxel-based analyses restricted to predefined regions of interest
(ROI) [28,32,33]. Four studies also included results on the association between grey matter loss and VH
or other cognitive variables [27,32–34]. Moreover, one study included only the comparison between
PD subgroups and controls [35], and another investigated progression of brain atrophy [34]. The
VBM methodology implemented was largely consistent between studies. All used the Statistical
Parametric Mapping (SPM) software for imaging analysis, and seven [21,25–28,31,35] used the
Diffeomorphic Anatomical Registration using Exponentiated Lie algebra (DARTEL) algorithm to
create a study-specific template. A threshold corrected for multiple comparisons was applied in four
whole brain [24,25,30,34], and four ROI [28,32,33,35] studies. The results of those studies which used
uncorrected thresholds [21,25–28,31] should be interpreted more cautiously, since analyses using an
uncorrected threshold may generate a higher number of false positives. Clinical and demographic
features, including severity of cognitive impairment, disease duration, age, and years of education
varied between studies. Some of them reported no differences between patients with and without VH in
global cognitive impairment [21,24,25,27,28,31,33], while others showed more severe cognitive decline
in hallucinating patients [30,32,34,35]. Furthermore, some studies on PD reported more advanced
disease stage (Hoehn and Yahr, H&Y, stage) in patients with VH than in those without [21,28,30,34].
Ibarretxe-Bilbao et al. investigated the progression of brain atrophy in PD patients with and
without VH [34]. Hallucinating patients presented more extensive grey matter loss over time,
accompanied by faster cognitive decline. Progressive grey matter reduction from baseline to follow-up
extended to parietal, temporal, frontal, thalamic, and limbic areas in patients with VH, whereas
only small clusters in frontal and cerebellar regions showed reductions in those without. Cognitive
impairment and disease severity at baseline, however, were greater in patients with VH than in those
without [34]. Additionally, significant associations between grey matter loss and cognitive functions
were detected in patients with VH, specifically in measures of learning (left hippocampus, r = 0.88),
delayed recall (left prefrontal cortex, r = 0.95), semantic fluency (left thalamus, r = 0.95), and language
comprehension (left amygdala, r = 0.89).
In a whole brain VBM study, Ramirez-Ruiz et al. found grey matter volumetric reductions in the
left lingual gyrus, and bilateral superior parietal lobe in PD patients with VH when compared with
those without (p < 0.05 corrected at the cluster level) [30]. In this study, PD patients were matched with
healthy controls. In this study, no information about the age of the included cohorts was given, and in
the comparison between hallucinating and non-hallucinating patients the authors do not appear to
have controlled for age in their analysis. Furthermore, patients with VH had more severe impairments
in global cognitive status (as measured by the Mini-Mental State Examination, MMSE [36]), more
advanced PD stage (rated with the Hoehn and Yahr scale [37]), and more severe depression (measured
by the Hamilton depression rating scale [38]) [30]. These variables were included as covariates in
the VBM statistical analyses [30]. Consistently with these findings, other studies reported decreased
grey matter volume in PD patients with VH, compared with those without, in occipito-temporal
regions, namely in the lingual and fusiform gyri, bilaterally [27,31]. Goldman et al. reported positive
associations between VH severity, and grey matter volume of the left parietal lobule, and cuneus, and
right lingual gyrus (p < 0.01 uncorrected) [27]. In addition to these findings, grey matter reductions
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have been reported in widespread brain areas, which were mainly located in the inferior parietal
lobes [21,27], cingulate cortex [27,31], frontal [25,31], temporal [25,31], and occipital [27,31] areas
bilaterally, and in the right supramarginal gyrus [21,31]. Another whole brain VBM study reported
differences between PD patients with and without mild VH (presence and passage hallucinations),
both decreases, mainly in the right vermis and precuneus, and increases, mainly in the cerebellum
and the left inferior frontal cortex were detected in patients with mild VH [29]. These VBM studies,
however, used thresholds uncorrected for multiple comparisons [21,25,27,31]. Differently from the
study above, Meppelink et al. did not detect a difference between non-demented PD patients with and
without VH [24], which may have been due to the more conservative threshold of p < 0.05 cluster-level
corrected for multiple comparisons being used in this study. These apparently contrasting findings
could, therefore, be a simple reflection of the application of a less rigorous statistical thresholding
approach by the studies reviewed above.
In addition to the whole brain studies described above, two VBM studies investigated
volumetric brain differences between hallucinating and non-hallucinating PD patients by using
an ROI approach [28,32]. Specifically, Janzen et al. investigated the grey matter volume of the
pedunculopontine nucleus due to its cholinergic function, thought to be involved in the development
of VH, and the thalamus as one of its projection areas [28]. The authors found reduced grey matter in
the left and right pedunculopontine nucleus between non-demented PD patients with and without
VH, but not in the thalamus by using a threshold corrected for multiple comparisons. Hallucinating
patients had significantly longer disease duration (VH: 11.5 ± 5.2 years; no VH 3.1 ± 3.6 years), were
at a more severe Hoehn and Yahr stage (VH: 2.5 ± 0.3; no VH: 2.1 ± 0.5) and were taking higher
levodopa equivalent doses. Furthermore, when hallucinating PD patients with and without dementia
were combined and compared with non-demented patients without VH, the reduction in volume
extended to the thalamus bilaterally [28].
In another voxel-based ROI study, the analyses were restricted to the hippocampus, due to its
link with dementia development [32]. This region was chosen since the presence of VH is thought to
be a risk factor for dementia, and therefore VH patients might exhibit the same pattern of atrophy
shown by patients with dementia. The authors reported no differences in the direct comparison of
non-demented PD patients with and without VH. When the two PD groups were independently
compared with healthy controls, only hallucinating patients showed reduced grey matter in the
anterior hippocampus bilaterally (p < 0.05 corrected); hippocampal volume also correlated with the
learning scores achieved on a verbal memory test [32]. Overall, however, the PD patients with VH had
more severe cognitive impairment, as shown by their lower MMSE scores and poorer scores on a verbal
memory test [32]. Negative findings were reported by another VBM study, which found no differences
in the hippocampus in any PD group, when compared with controls [35]. These contrasting findings
might be due to differences in clinical and demographic variables—such as cognitive performance,
disease duration, and age—and methodological differences in the analyses (i.e., standard VBM vs.
DARTEL). In the latter study, when PD patients with and without VH were compared separately with
healthy controls, using an ROI approach with ROI in temporal and frontal areas, reduced grey matter
was found in the left superior frontal gyrus in both PD groups, while reduction in grey matter in the
left frontal operculum was detected only in hallucinating patients [35]. The two PD groups, however,
differed from each other in some clinical variables—including global cognitive level (measured with
the MMSE), motor symptoms (evaluated with the Unified Parkinson’s Disease Rating Scale motor
score subsection, UPDRS III [39]), and depression (assessed with the Beck Depression Inventory,
BDI [40])—with the hallucinating group being more severe in all these measures [35].
Only two studies used VBM to investigate differences between hallucinating and
non-hallucinating patients with DLB [26,33]. Despite the small sample size (six DLB with VH, six
without VH), Sanchez-Castaneda et al. [33] found a reduction of grey matter volume in the right inferior
frontal gyrus in hallucinating patients (p < 0.05 corrected) using a voxel-based ROI approach. In the
same study, patients with PDD presented grey matter volumetric reductions in the left orbitofrontal
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cortex, which was no longer significant when controlling for age [33]. In the hallucinating DLB
subgroup, VH severity was strongly associated with reduction in the volume of the right inferior
frontal gyrus (r = 0.89) and left precuneus (r = 0.95), while no significant correlations were found in the
PDD subgroup. Another VBM study in DLB identified volumetric grey matter reductions posteriorly,
in the left cuneus, by using a whole brain approach [26]. These findings, however, should be taken
with caution as the threshold used in this study was not corrected for multiple comparisons. Moreover,
demographic and clinical comparisons between patients with and without VH were not reported,
probably due to the exploratory nature of the analysis of VH (the main aim of the study was to compare
DLB with Alzheimer’s disease, AD, patients and with controls) [26].
3.1.2. Other Structural MRI Studies
In addition to the VBM studies described above, other studies have investigated brain
morphological features of predefined ROI, especially their overall volume [18–20,22,24,41,42], and
shape [22] in LBD. Three studies examined group differences in cortical thickness using the Freesurfer
software package (and adopting thresholds corrected for multiple comparisons) [16,17,43]. Seven
studies investigated volumetric [20,22,24,25,42] or cortical thickness [16,17] differences between PD
patients with and without VH. Only three studies focused on the comparison between DLB and AD
patients, and reported an association with VH indices [18,19,41,43].
Medial temporal lobe (MTL) structures, especially the hippocampus, were investigated by
five studies [18,19,22,41,42]. Two of them focused on PD, and argued for an involvement of the
hippocampus in the formation of VH mainly based on its role in memory, and evidence suggesting
the presence of a high burden of Lewy body pathology in this region [22,42]. Yao et al. [22] used a
multimodal MRI approach to investigate hippocampal volume, shape, mean diffusivity (MD), and
functional connectivity. The authors found no differences between groups (PD with and without
VH, and controls) in hippocampal volume and shape (MD and functional connectivity results are
described in subsequent sections). Another MRI study reported significant volumetric reduction in
hippocampal substructures, namely CA2-3 and CA4-DG, in PD patients with VH compared with
those without [42]. Differences in the hippocampus as a whole were reported, however, only when
hallucinating patients were compared with healthy controls. The more severe cognitive impairment
in patients with VH, however, might have affected the results [42]. The value of the findings of these
studies is limited by the relatively small size of the samples included in both studies [22,42]. Three
MRI studies investigated the association between VH indices in DLB and MTL [18], hippocampus [19],
and hippocampal substructure volumes [41]. A negative correlation was reported between severity of
VHs and volumetric measures in MTL (entorhinal cortex, hippocampus, and amygdala) [18]. However,
these three studies failed to report a priori hypotheses based on the involvement of MTL regions in the
development of VH, probably because VH were not the primary objective of investigation.
Lee et al. [20] selected five ROI within the visual pathway to investigate differences between
hallucinating and non-hallucinating PD patients in the optic chiasm area, lateral geniculate nucleus,
and V1 volumes and white matter microstructure features in the optic nerve and optic radiation (the
latter are described in Section 3.1.3). These regions were selected to examine the neural bases of VH
in relation to their role in processing visual information. Volumetric reductions in VH patients were
reported only in the lateral geniculate nucleus [20]. In addition to the whole brain analysis described
in the previous section, Meppelink et al. focused on an ROI in the left fusiform gyrus, detecting no
differences between PD with and without VH [24]. Finally, another structural MRI study carried out
an ROI analysis by delineating the left and right substantia innominata boundaries (in addition to the
VBM analysis reported above) and identified a smaller volume of this structure in hallucinating PD
patients (46 PD with VH, 64 PD without VHs) [25]. Furthermore, the volume of this region correlated
with scores on verbal memory, semantic fluency, and go/no-go tests [25].
Studies investigating cortical thickness did not detect any differences between PD patients
with and without VH [16,17]. However, when hallucinating PD patients were compared with
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non-hallucinating patients at a less advanced disease stage (H&Y; PD with VH: 3.0 ± 0.5; no VH: 2.1
± 0.4) and controls, reduced cortical thickness was reported in frontal and parietal regions [16]. In
the latter study, the analysis was restricted to regions within the default mode network (DMN) [16].
On the other hand, Yao et al. [17] found no differences between PD subgroups and controls in the
analysis of the whole cortical surface. Finally, Delli Pizzi et al. [43] found a significant association
between the Neuropsychiatric Inventory (NPI) [44] hallucination score, and cortical thickness in right
lateralised parietal regions, namely the precuneus, and superior parietal gyrus in DLB patients (p < 0.05
corrected).
3.1.3. Diffusion Tensor Imaging
Four DTI studies were found, two on PD [20,21], and two on DLB [45,46]. Three studies
investigated predefined ROIs of grey or white matter [20,45,46], while only one used a whole
brain approach, namely tract-based spatial statistics TBSS (using a threshold corrected for multiple
comparisons) [21]. Most of the studies used the FMRIB software library (FLS) for DTI analysis [20,21,45].
One study did not include a sample of LBD patients without VHs, and hallucinating patients where
compared to healthy controls and AD [45].
Lee et al. [20] reported disrupted white matter integrity in the right optic nerve, and in the left
optic radiation by using an ROI approach. In another multimodal study (VBM analysis reviewed
above), Lee et al. [21] performed voxelwise analysis of fractional anisotropy (FA) and MD by using
TBSS. No differences were found between non-demented PD subgroups with and without VH, and
a similar pattern of abnormalities was reported when independently compared with age-matched
healthy subjects, specifically in fronto-temporo-parietal and brainstem regions [21]. In these two
studies, PD with and without VH did not differ for age, disease duration, MMSE score, and motor
symptoms [20,21], but in one of these studies hallucinating patients were at a more advanced
disease stage than non-hallucinating patients [21]. From the articles, however, it could not be
established whether some of the patients investigated in the latter two references were the same
in both studies [20,21].
Although DTI is mainly used to investigate microstructural white matter abnormalities, two
studies focused on grey matter [22,45]. Yao et al. [22] reported increased MD in the right hippocampus
in hallucinating PD patients. Moreover, Delli Pizzi et al. [45] investigated grey matter MD differences
between DLB patients with VH and healthy controls by using a tractography-based subdivision
of the thalami. The authors found increased MD in thalamic sub-regions projecting to prefrontal,
parieto-occipital cortex (bilaterally), amygdala (right lateralised), and motor cortex (left lateralised).
Moreover, MD in the right thalamic sub-region projecting to parietal and occipital cortex was associated
with severity of VHs [45]. Finally, among the studies that focused on DLB, Kantarci et al. [46] showed
increased MD in the inferior longitudinal fasciculus in patients with VHs compared with those without.
Demographic and clinical differences between these groups of patients were not reported, however,
probably because the main purpose was to differentiate DLB and AD patients [46].
3.2. Functional Brain Imaging
A total of 37 studies undertook functional imaging focusing on VH in LBD, including studies
using task-based and resting-state fMRI, PET, and SPECT.
Details regarding demographic, clinical, and methodological information, and imaging results
related to VH are reported in Table A2 for each study.
3.2.1. Task-Based fMRI
Ten studies used fMRI to identify brain activation patterns in response to simple visual
stimuli [23,47–50], perception recognition tasks [51–53], and two single cases during VH [54,55].
The majority of them were in PD [48–54], while only three included patients with DLB [23,47,55]. Two
studies performed different analyses on the same sample of DLB patients who had performed a visual
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task in the scanner [23,47]. Methodology and fMRI paradigm differed between studies, which may
partly account for some inconsistencies in the findings. Other differences between studies include
the threshold used to report the results, age, cognitive impairment, and duration of the disease. One
study described in this section included PD patients experiencing minor VHs, including sensation of
passage, presence, or misperceptions [49].
Five studies examined blood-oxygenation level-dependent (BOLD) signal in response to simple
visual stimuli [23,47–50]. Specifically, they investigated the perception of moving stimuli [23,47,48],
apparent motion [50], circular gratings [49], checkboards, objects [47], and stroboscopic stimulation [50].
Regions of both increased and decreased activation were found in hallucinating PD patients, compared
with the non-hallucinating ones [48–50]. The most consistent finding was decreased activity in occipital
and temporal regions [48–50], even though increases in occipital [49], and temporal [48] areas were
also reported. One of these studies, however, had a very small sample size (three PD with VHs,
three PD without VHs) [48]. In addition, reduced activity was found in the parietal and cingulate
cortex [50]. On the other hand, increased activity was reported mainly in the frontal lobe [49,50].
Two studies focusing on DLB reported no correlation between BOLD signal and VH indices, but no
comparison with patients without VHs was performed [23,47]. One of the latter studies reported
a negative association between the NPI hallucination score and perfusion in V4, detected by using
arterial spin labelling (ASL)-MRI [23].
Three studies on PD focused on perceptual recognition of complex visual stimuli [51–53].
In comparison with non-hallucinating patients, those with VH presented decreased activity in
the right superior frontal gyrus (p < 0.05 cluster-level corrected) during perceptual recognition of
faces [52], animals, and objects [51]. In addition to these regions, decreased activation was found in
the right inferior frontal (face recognition) [52], left lingual, and bilateral fusiform gyri (animal/object
recognition) [51]. In one of these studies [52], however, patients with VH had more severe cognitive
impairment and behavioural performance (fMRI task) than those without, which might have partially
affected the results. Shine et al. [53] identified dysfunctional connectivity in and between attention
networks and the DMN during the bistable percept paradigm (BPP) in PD patients with VH [53].
During this task, patients were asked to discriminate between images containing only one perceptual
interpretation (stable, e.g., a candlestick) and images containing more than one (bistable, e.g., two
faces and a candlestick) [53]. In this study, PD patients were divided into two groups according to the
percentage of misperceptions at the BPP. Patients performing above a previously established cut-off
score [56] also presented clinically assessed VH, while those performing below did not [53].
Two fMRI studies recorded brain activity during the occurrence of visual hallucinations in single
cases [54,55]. Both patients experienced complex VH, namely seeing animals [54,55] and people [54]
in the MRI scanner. Howard et al. [55] scanned a DLB patient in the hallucination-free state (the
patient was taking risperidone), and a second time whilst he was hallucinating (seven days after
risperidone was stopped). They found decreased activation in V1 and V2 in response to photic
stimulation while the patient was hallucinating compared with the hallucination-free scan [55]. On
the other hand, Goetz et al. [54] performed an event-related design in order to compare hallucinating
and non-hallucinating events in a patient with PD. While the patient was experiencing VH, decreased
activity was reported mainly in occipito-temporal areas, but activity increased in the anterior and
posterior cingulate cortex [54].
3.2.2. Resting-State fMRI
Seven studies [16,17,22,57–60] performed resting-state fMRI analysis, including five statistical
comparisons between patients with and without VH in PD [16,17,22,59,60]. Only two studies included
a sample of hallucinating DLB patients and adopted correlational analyses [57,58]. Heterogeneity in
methodology was found between studies. Specifically, independent component analysis (ICA) [16,17],
ROI, and seed-based analyses [16,22,60] of functional connectivity, amplitude of low-frequency
fluctuation (ALFF) [16,60], and graph analysis [58] were used. Moreover, between-study differences
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were detected for age, disease duration, motor symptoms, and global cognitive impairment, even
though patients with and without VH were usually well matched within single studies. In addition,
overall sample sizes were relatively small.
Two resting-state fMRI studies investigated differences between PD patients with and without
VH in the functional connectivity of the DMN [16,17]. In both studies, the DMN was identified
by performing ICA. The methodology implemented to investigate group differences in functional
connectivity, however, was different. Specifically, in Franciotti et al. [16] pairwise ROI centred on the
DMN were compared between groups. On the other hand, Yao et al. more broadly investigated the
differences in the spatial map of the DMN [17]. Both studies reported increased functional connectivity
in hallucinating patients in comparison with the non-hallucinating ones, mainly in fronto-parietal
regions. Specifically, Franciotti et al. [16] detected increased connectivity between the superior frontal
sulcus bilaterally with ipsilateral and contralateral parietal regions, and also between contralateral
parietal regions. Yao et al. found increased activity in the right superior middle frontal lobe and bilateral
precuneus and posterior cingulate gyrus within the DMN (p < 0.05 corrected) [17]. Both PD patients
with and without VH presented a pattern of decreased functional connectivity when independently
compared to healthy controls [16,17]. Furthermore, results from another resting-state fMRI study [59]
were consistent with an association between VH and disrupted activity of the DMN, and other
attention networks. The authors performed regression analyses to investigate the association between
misperceptions at the BPP (the paradigm described above in Section 3.2.1) [56] and resting-state
networks connectivity. All patients performing below a predefined BPP cut-off were also clinically
classified as hallucinating. BPP error scores predicted connectivity between the ventral attention
network (VAN) and the dorsal attention network (DAN), and increased connectivity within the DMN
and the VAN [59].
In addition to the functional connectivity analyses reviewed above, Franciotti et al. [16] also
investigated the fractional ALFF on the DMN centred ROI. Compared with non-hallucinating patients,
PD with VH presented higher spectral power in fronto-parietal areas bilaterally [16]. Yao et al. [60]
performed spectral analysis on the same sample in a previous study [17], reviewed above in
Section 3.1.2. They found increased ALFF in VH patients in areas located in the cerebellum, temporal,
and parietal lobes. Decreased ALFF was reported in occipital regions, namely the lingual gyrus, and
cuneus bilaterally. These latter results were used to perform seed-based functional connectivity analysis.
Compared with controls, both PD groups showed decreased functional connectivity, but in VH patients
it was increased when compared with non-hallucinating patients [60]. In a multimodal MRI study,
Yao et al. [22] reported both increased and decreased functional connectivity of the hippocampus in
patients with VH compared with those without, using a seed-based approach. Specifically, increased
connectivity was found with fronto-parietal regions, while it was decreased with occipito-temporal
areas [22]. When compared to controls, however, both PD subgroups presented decreased connectivity
of the hippocampus, bilaterally [22]. These latter studies performed different analyses on the same
cohort of patients and this needs to be taken into account when interpreting the results [17,22,60].
Yao et al. [22] also performed correlational analyses between cognitive measures and the regions
of differential connectivity between PD groups. Specifically, the functional connectivity of the
right hippocampus with right occipital, and medial temporal areas was negatively associated with
visuospatial memory performance, which was in turn associated with VH severity [22]. On the other
hand, other studies found no association between measures of VH and functional connectivity within
regions in the DMN in PD [17], and in the temporal network in DLB [57]. Peraza et al. [58] explored
functional connectivity in DLB by using a graph theory approach. They found no significant correlation
between the NPI hallucination score and integrated global network measures [58]. However, they
found an association with local network measures of node degree (negative for the left postcentral gyrus
and positive for the putamen), and nodal betweenness centrality (negative for the right intracalcarine
cortex and positive for the fusiform cortex) [58]. In another study, Peraza et al. performed secondary
analyses on VHs in DLB, which showed an association between the NPI hallucination score and the left
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fronto-parietal, and sensory-motor networks [57]. It is not clear whether for two of the latter studies a
subsample of the patients was from the same cohort of patients or not [57,58].
3.2.3. Positron Emission Tomography
We identified 11 studies investigating regional cerebral glucose metabolism using PET. Among
them, six focused on the differences between patients with and without VH, four in PD [61–64], and
two in DLB [65,66]. Other studies examined associations between glucose metabolism and VH indices,
such as severity and frequency [18,19,64,67,68]. Among the voxel-wise whole brain analyses, three
out of five studies compared subgroups of patients [61–63], and one out of three used a correlation
approach [67] and used thresholds corrected for multiple comparisons. Overall, sample sizes were
relatively small.
PD patients with VH presented hypometabolism mainly in posterior regions, especially in the
parietal and temporal lobes [61,62,64]. The bilateral precuneus and lingual gyrus were particularly
affected [61,62]. Gasca-Salas et al. [62] also reported two smaller clusters in the right occipital
lobe, while Boecker et al. [61] reported frontal hypometabolism in VH patients. In contrast,
Nagano-Saito et al. [63] found frontal hypermetabolism, specifically in the left superior frontal gyrus.
Discrepancies might be partially explained by differences in demographic and clinical features
between studies, including age, disease duration, and global cognitive impairment. Moreover, in
Boecker et al. [61], hallucinating patients were at a more advanced disease stage, and had more severe
motor symptoms than non-hallucinating patients. However, UPDRS III scores were included as
covariate of no interest in the statistical analysis [61]. Only two studies compared DLB subgroups and
reported contrasting findings. In a whole brain analysis, Perneczky et al. [66] showed hypometabolism
in right lateralised temporo-occipital and frontal regions. Although results from the latter study
were not corrected for multiple comparisons, differences were only expected in regions found to be
hypometabolic when compared with controls (occipital, temporo-parietal, and frontal areas) [66]. In
contrast, Imamura et al. [65] reported increased regional cerebral glucose metabolic rate in temporal
and parietal regions. In the latter study, however, patient groups significantly differed in MMSE scores
(DLB with VH: 19.5 ± 3.9; no VH: 15.0 ± 3.0; AD: 19.7 ± 3.5) [65]. Moreover, different methods were
used, namely whole brain voxel-wise comparisons [66] and ROI analyses [65]. In addition to these
findings, a PET study divided DLB patients into two subgroups, based on the hypermetabolism of
peri-motor areas, cerebellum, and basal ganglia. The group with more regions of hypermetabolism
was associated with more frequent VHs [69].
Studies investigating correlations between glucose metabolism and VH indices mainly reported
negative associations with posterior regions [18,19,64,67,68]. Specifically, occipital hypometabolism
has been related to severity [67] and frequency [19,67] of VH. A negative correlation with the NPI
hallucination score has also been found in parietal [68] and temporal regions [64]. Finally, Iizuka
and Kameyama [18] found a negative association with the standardized uptake value ratio in the
precuneus/cuneus (r = −0.62, p < 0.01), and a positive association with the cingulate island sign ratio
on [18F]-Fluorodeoxyglucose (FDG)-PET (r = 0.44, p < 0.05).
3.2.4. Single Photon Emission Computed Tomography
Regional cerebral blood flow in LBD patients with VHs has been investigated by nine SPECT
studies, four on PD [70–72], five on DLB [73–76], one on PDD and DLB combined [77], and a single
case on PDD [78]. Six studies examined the differences between hallucinating and non-hallucinating
patients, three whole brain analyses [70,71,73] and three ROI analyses [72,74,76]. Different tracers were
used to investigate cerebral blood flow using SPECT, including N-isopropyl-p-[123I]iodoamphetamine,
[99mTc]ethyl cysteinate dimer, and 99mTc-HMPAO. Three studies investigated areas of association
between perfusion and VH indices [73,75,77] and one study performed a SPECT scan during
VH [78]. Overall, hallucinating patients showed regions of reduced brain perfusion compared with
non-hallucinating patients. Only two studies reported no differences between groups [72,74].
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Occipital hypoperfusion has been reported in both hallucinating PD [70] and DLB [73,76] patients,
even though these studies present some limitations. For example, one only reported demographic
and clinical characteristics of DLB and AD, without differentiating between patients with (n = 26) and
without (n = 4) VH [76]. Moreover, Heitz et al. performed whole brain analyses without correcting
the results for multiple comparisons [73]. Other ROI SPECT studies found no differences in occipital
perfusion [72,74]. In another whole brain SPECT study, Oishi et al. [71] compared PD patients with
(n = 24) and without (n = 41) VH. The authors found reduced cerebral blood flow in the right fusiform
gyrus, which remained significant when correcting for multiple comparisons. Other temporal and
parietal regions were found to be different between groups by using an uncorrected threshold [71]. In
another whole brain study, O’Brien et al. [77] investigated the relationship between changes in brain
perfusion and hallucinations over one year in a combined group of patients with DLB and PDD. They
found a negative association with left parietal regions, namely the posterior cingulate gyrus and the
precuneus (p < 0.05 cluster-level corrected) [77]. Another SPECT study performed factor analysis in
order to investigate associations between regional cerebral blood flow and psychotic symptoms in
DLB [75]. The authors showed a relationship between parietal and occipital hypoperfusion, and the
sense of presence and hallucinations of people, but not of animals, insects and objects [75]. Finally,
Kataoka et al. [78] described a patient with PDD having VHs during a SPECT scan, showing increased
regional cerebral blood flow in the temporal lobe bilaterally, and in the left inferior frontal gyrus.
4. Discussion
The aim of the present review was to provide an overview of the neuroimaging findings from
studies, which have investigated the neural bases of VHs in LBD by critically reviewing the current
literature in the field. What emerged is that LBD patients with VH are characterized by widespread
structural and functional brain abnormalities in cortical, but also subcortical regions. Given the more
limited evidence in DLB and PDD than PD without dementia, it is difficult to infer disease-specific
mechanisms within the LBD spectrum. A summary of the most consistent neuroimaging findings
associated with VHs in LBD patients is shown in Table 1.
Table 1. Summary of the most consistent findings associated with VHs in LBD.
Brain Regions GM Volume FunctionalConnectivity
Task-Related
BOLD
Activation
Glucose
Metabolism
Brain
Perfusion
Frontal ↓ ↑ ↑↓ ↓↑
Parietal ↓ ↑ ↓↑
Temporal ↓↑
Occipito- temporal ↓ ↓↑ ↓
Occipital ↓↑ ↓
BOLD: blood-oxygenation level-dependent; GM: grey matter; LBD: Lewy body disease; VH: visual hallucinations;
↓: decrease; ↑: increase.
Overall, the most consistent finding among structural MRI studies of VH in LBD is grey matter loss
in frontal areas, mainly in patients with dementia [33], and parietal and occipito-temporal regions [30]
in non-demented PD patients. The presence of frontal and parietal impairment is consistent with
results reported by neuropsychological studies showing more severe deficits in executive functions
and visual attention in hallucinating patients [79–82]. This is in line with multifactorial models of VHs,
proposing a role of visual attention deficits and disrupted engagement of attention networks in the
development of VHs [5,83].
Notably, cholinergic treatment has been shown to ameliorate VHs and cognitive functioning,
especially attention [84], corroborating the hypothesis of an involvement of attention dysfunction
in the development of VH. Collerton et al. [5] proposed the Perception and Attention Deficit model,
and suggested that VH result from the combination of impaired top-down and bottom-up processes,
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specifically coexisting deficits in attention and visual perception. These deficits would be supported
by impaired activity in the lateral frontal cortex, and the ventral visual stream, respectively [5].
Surprisingly, given the established deficits in visual perception in LBD patients with VH [34,85–87],
evidence of structural grey matter and brain metabolism differences in the occipital lobe is limited.
Occipito-temporal and parietal grey matter loss, and reduction of cerebral blood flow were present
mainly in PD [30,71]. Occipital hypoperfusion detected by SPECT has been reported [70,73,76], even
though negative findings were also reported [72,74]. Discrepancies were reported in resting state
FDG-PET studies. The most consistent finding is parietal and temporal glucose hypometabolism
in PD with VH, even though inconsistencies were shown in frontal areas. The findings of these
studies were both decreased and increased metabolism in the same regions in DLB, which might
reflect demographic, clinical, and methodological differences between studies. In summary, resting
state functional studies point towards hypometabolism/reduced blood flow in occipito-temporal and
parietal regions in LBD patients with VH. This dysfunction in visual association regions might play a
role in the genesis of VHs in LBD. This finding is further supported by the demonstration of disrupted
white matter integrity in hallucinating DLB patients in the inferior longitudinal fasciculus [46], a
bundle of associative fibres that connects the occipital and temporal lobes, which has been related to
visual memory and perception [88].
To date, only a few studies have investigated how resting-state networks are disrupted in VH,
and these studies have focused mainly on PD. Overall, increased functional connectivity in the
DMN has been shown in hallucinating patients compared with those without hallucinations, while
reduction in functional connectivity was a consistent finding in both PD subgroups when compared
with healthy controls. Therefore, dysfunctional increased connectivity might play a significant role
in the genesis of VH, especially within the DMN and fronto-parietal regions [16,17]. A speculative
interpretation can be put forward, suggesting that a dysfunctional compensatory mechanism, resulting
in increased functional connectivity in hallucinating patients, may foster the emergence of these
symptoms. Functional abnormalities in frontal, temporo-occipital, and occipital areas have been
reported by task-based fMRI studies. The direction of such alterations in the BOLD signal activity is
still unclear, however, which might be due to differences in the behavioural tasks and in the stimuli
used in the different studies.
Taken together, the results of imaging studies in LBD patients with VH are scarce for DLB
but more frequent for PD. There is a mismatch between a more prominent involvement of primary
and association visual regions in brain metabolism and blood flow studies and a more prominent
involvement of more frontal regions when studying GM volume or cortical thickness. None of
these findings appears to be associated with a different burden of neuropathological changes.
In fact, despite the association between Lewy body pathology and VH in medial temporal lobe
areas [11–13], substantial structural alterations in these regions have not emerged from this review.
Neuropathological findings have shown a negative association between Lewy body pathology and
regional brain atrophy, specifically in the frontal lobe, but conflicting evidence has been reported for
the amygdala [89,90] and no associations have been found with occipital lobe dysfunction. Neither
the macrostructural alterations observed with MRI nor the functional PET/SPECT findings, therefore,
appear directly informative of the different underlying cellular events and neuropathology [91]. We
can, therefore, speculate that VH in LBD emerge only in the presence of a double hit—i.e., concomitant
alterations of large functional and structural attentional networks—of which frontal lobe atrophy may
be a surrogate marker, and dysfunction of visual information processing, of which occipital-temporal
and parietal hypometabolism is the functional hallmark. Large attentional networks may be impaired
by diffuse cortical deposition of synuclein, and even amyloid. The cause of reduction in metabolism
in posterior brain regions—i.e., which crucial cortical or subcortical projections are deafferenting the
occipital cortex—remains still unexplained.
Visual hallucinations in LBD have been consistently associated with cognitive impairment. Firstly,
their prevalence was found to be significantly higher in patients with dementia, and cognitive decline
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has been shown to be a significant predictor of VH [92,93]. In addition, there is an increased risk of
developing dementia in PD in patients with early hallucinations [94]. LBD patients with VH have more
severe deficits in a number of cognitive domains, especially visual perception and visual attention
in both DLB [79,86,87] and PD [34,81,95–97], executive functioning [80,82,98,99], and long-term
memory [80–82] in PD. Therefore, an important future development of research in this field may
be the study of the association between cognitive functions and brain regions and networks specifically
altered in LBD patients with VHs.
A limitation of the current literature in the field is that there have been only a few studies
investigating structural brain alterations related to VH in DLB. In particular, only two studies compared
patients with and without VHs directly [33,46], and no whole brain VBM analysis to date focused on VH
in DLB. The neuroanatomical correlates of this symptom were assessed more extensively in PD. Further
research is, therefore, needed to clarify better how these structural changes are related to cognitive
functioning and connectivity between brain regions. This may be achieved by integrating studies
using different imaging techniques, specifically resting-state fMRI and DTI, for the simultaneous study
of functional and structural connectivity respectively. Although some resting-state fMRI studies were
conducted in PD, none is available in which DLB patients with and without VHs have been directly
compared. Similarly, lack of DTI studies examining white matter integrity emerged from this literature
review. Future studies may benefit from the investigation of functional and structural networks
associated with those cognitive functions impaired in patients with VHs. To our knowledge, only a
few studies have explored the relationship between cognitive functioning and brain abnormalities
in hallucinating LBD patients [22,25,32,34]. Other studies performed correlational analysis using
clinical variables, especially VH severity and frequency, which have been mainly associated with
parietal regions by both structural [27,33,43] and functional studies [18,57,68,77], but other correlational
analyses showed no relationship with any brain region [17,19,41,46,47,58]. Furthermore, most of the
studies reviewed above used the NPI questionnaire, which is not specific to capture the whole spectrum
of phenomenology of VHs in this disease. Therefore, a more accurate evaluation of this symptom
might be beneficial in the investigation of the neural correlates of visual hallucination. For example,
the North-East Visual Hallucinations Interview (NEVHI) is a semi-structured interview, which was
designed specifically to assess VH in older people with cognitive impairment [100] and this instrument
might be more accurate to fine grain VH in LBD.
Finally, the present review itself presents some limitations. Even though negative results were
reported by some studies, publication bias cannot be completely ruled out. In addition, we tried to
reduce selection bias by undertaking an extensive literature search in two different databases with
no time limit. Despite this, the possibility of having missed suitable studies cannot be fully excluded.
We reviewed neuroimaging studies which had analysed VH in LBD that met the inclusion criteria.
However, not all the studies had VH as their primary focus of investigation (e.g., analysis on VH in
studies assessing differences between different types of dementia), and several studies failed to report
clearly stated a priori hypotheses on the mechanisms underlying VH. Moreover, studies performing
whole brain analyses were included even when results were not corrected for multiple comparisons,
which may increase the occurrence of false positives. These factors, together with the inclusion of small
sample sizes and other methodological limitations (e.g., statistical analyses not including covariates of
no interest) might contribute to lowering the overall quality of the records included.
5. Conclusions
VHs are severe and disabling symptoms frequently observed in patients with LBD. The present
review provides an up to date summary of current knowledge about the neural bases of VH in
LBD. Overall, the findings suggest the involvement of structural and functional alterations in several
brain areas in frontal, parietal, and occipito-temporal cortex. The mechanisms underlying VH in
LBD, especially in patients with dementia, and how these differ between conditions remain still
unclear, however. Future research might benefit from a combined investigation of structural and
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functional connectivity, as well as its association with neuropsychological measures. This might aid
the understanding of the pathophysiology underlying VH in LBD and its relationship with cognitive
decline. Neuroimaging techniques might help in the detection of symptom-specific biomarkers, which
might be used to assess efficacy of treatments in the future, and as targets for new interventions.
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Appendix A
Table A1. Summary of structural neuroimaging studies of hallucinating patients with LBD. Only main results related to VH are reported.
Study Sample Age 1
Disease
Duration
(years) 1
VH MMSE 1 H&Y Neuroimaging Methods—VH
Main Results:
Neuroimaging and VH
Blanc et al.
(2016) [26]
28 pro-DLB 67.5 (9.2)
NA
60.7% DLB
patients
27.6 (2.1)
NA
Whole brain VBM
Covariates: age, TIV, sex, group comparison
Grey matter volume
p ≤ 0.005 uncorrected
VH < NVH: L cuneus
27 pro-AD 69.3 (7.8) 26.9 (1.9)
33 HC 72.4 (10.4) 29.4 (0.9)
Delli Pizzi et al.
(2016) [41]
19 DLB VH 76.37 (4.35) 2.95 (0.91)
NPI
18.00 (4.83)
NA
ROI MRI
ROIs: hippocampal substructures; covariates: age,
ed., TIV; relationship with NPIhall
Grey matter volume
Correlation with NPIhall: NS
15 AD 76.47 (7.17) 3.00 (0.93) 16.73 (6.31)
19 HC 76.21 (4.49) - 27.58 (0.69)
Delli Pizzi et al.
(2014) [43]
18 DLB VH 75.4 (4.0) 2 2.9 (0.6) 2
NPI
19.1 (2.6) 3,4
NA
Cortical thickness
Covariates: MMSE, CAF, and UPDRS; correlation
with NPIhall (entire cortex and ROI where DLB 6= AD)
Cortical thickness
p < 0.05 corrected
DLB VH < HC: bilat. pericalcarine, LG, cuneus,
precuneus, SPG
Correlation with NPIhall: R precuneus and SPG
15 AD 75.6 (7.6) 3.1 (0.6) 18.3 (4.1)
14 HC 75.5 (5.3) - 28.1 (1.6)
Delli Pizzi et al.
(2014) [45]
15 DLB VH 76.3 (4.1) 2 2.9 (7) 2
NPI
17.7 (5.2) 4,5
NA
DTI ROI
Tractography-based subdivision of the thalami;
nuisance factors: MMSE, CAF, and UPDRS;
correlation with NPIhall
Grey matter MD
DLB VH > HC: thalamic sub-regions project. to PFC and
parieto-occipital cortex bilaterally; R thalamic region
project. to amygdala; L thalamic region project. to motor
cortex
Positive association with NPIhall: R thalamus to parietal
(VH freq. and sev.) and occipital cortices (VH sev.)
15 AD 76.1 (4.9) 3.1 (6) 16.7 (5.4)
13 HC 76.0 (4.2) - 28.3 (1.5)
Franciotti et al.
(2015) [16]
15 sPD VH 70 (6) 2 11.3 (4.3) 6,7
NPI and
semi-structured
interview
24.3 (2.2) 2 3.0 (0.5) 7 Cortical thickness
Analysis within DMN cortical regions; nuisance
factor: age; group comparison
Resting-state fMRI 8
Cortical thicknesss
sPD VH vs. sPD NVH: NS
sPD VH < ePD: L SFS and IPL, bilat. MFG, LPC
sPD VH < HC: L SFS, bilat. MFG, LPC, IPL, PCC
sPD NVH < HC: R LPC, bilat. IPL, PCC
15 sPD NVH 68 (11) 12.0 (4.5) 7 24.7 (1.8) 3.0 (0.6) 7
15 ePD NVH 66 (9) 3.3 (1.8) 26.2 (1.8) 2.1 (0.4)
15 MSA 67 (5) 3.9 (1.8) 25.2 (1.7) 3.2 (0.8)
15 HC 69 (6) - 28.7 (0.7) -
Gama et al.
(2014) [35]
11 PD VH 70.6 (9.1) 2 7.4 (6.1) 2
Based on
definition of
VH
19.3 (3.7) 9
From stage I to
stage IV
ROI VBM
ROIs (SVC): temporal and frontal regions; group
comparisons
Grey matter volume
p < 0.05 corrected
VH < HC: L opercula and SFG
NVH < HC: L SFG
28 PD NVH 65.7 (7.8) 6.5 (5.0) 25.6 (4.3)
10 HC 68.1 (7.0) - 25.6 (4.3)
Goldman et al.
(2014) [27]
25 PD VH 74.8 (6.0) 2 13.1 (4.6) 2
MDS-UPDRS
23.9 (5.4) 2 3 (2-5) 2,10 Whole brain VBM
Covariate: TIV; group comparison; association
between regions where VH < NVH and VH sev.
Grey matter volume
p < 0.01 uncorrected
VH < NVH: bilat. occipital, occipito-temporal, and
parietal regions
Correlation with VH sev.: parietal, occipital, and
occipito-temporal regions
25 PD NVH 75.4 (6.1) 10.8 (4.4) 25.1 (4.4) 3 (2-5) 10
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Table A1. Cont.
Study Sample Age 1
Disease
Duration
(years) 1
VH MMSE 1 H&Y Neuroimaging Methods—VH
Main Results:
Neuroimaging and VH
Ibarretxe-Bilbao
et al. (2010) [34]
12 PD VH 73.3 (5.9) 2 12.1 (5.7) 2
Structured
interview; NPI
26.9 (1.9) 4,9,11 3.1 (1.1) 9
Whole brain VBM
Covariate: MMSE; comparison between baseline and
follow-up in each group; correlations between
atrophy progression and cognitive decline in PD VH
Grey matter loss form baseline to follow-up
p < 0.05 corrected
VH: bilat. parietal cortex, insula, STG, ITG, SFG, IFG,
thalamus and limbic areas, L dorsal PCC
NVH: R frontal areas and cerebellum
Correlations with grey matter loss in PD VH: learning
with L hippocampus, delayed recall with L prefrontal
cortex, semantic fluency with L thalamus, language
comprehension with L amygdala
14 PD VH 71.1 (5.7) 11.9 (4.3) 29.3 (1.6) 2.3 (0.5)
12 HC 70.7 (7.2) - 29.5 (2.6) -
Ibarretxe-Bilbao
et al. (2008) [32]
16 PD VH 73.5 (5.1) 2 12.9 (5.9) 2
Structured
interview
26.0 (2.1) 4,9 3.2 (1.1)
ROI VBM
ROI: hippocampus; group comparison; correlation
analysis with cognitive measures
Grey matter density
p < 0.05 corrected
VH vs. NVH and NVH vs. HC: NS
VH < HC: bilat. anterior hippocampus
Correlation with grey matter loss in anterior
hippocampus bilaterally: learning scores in patients with
PD VH, but not PD NVH and PDD
19 PD NVH 72.5 (5.8) 10.9 (4.2) 28.2 (1.7) 2.5 (0.7)
9 PDD 69.8 (9.5) 13.1 (5.4) 15.7 (5.4) 3.8 (1.0) 12
56 HC 73 (6.7) - 28.7 (3.1) -
Iizuka and
Kameyama
(2016) [18]
24 DLB 73 (68, 79) 13 2.8 (1.8, 3.2) 13
NPI
23 (20.5, 24) 13
NA
ROI MRI
ROI: medial temporal lobe, correlation analysis
PET 8
Negative correlation with NPIhall in DLB: MTL atrophy
24 AD 74 (69, 81) 13 2.3 (1.6, 2.6) 13 23 (21, 24.5) 13
Janzen et al.
(2012) [28]
13 PD VH 66.0 (6.9) 2 11.5 (5.2)
SCOPA-PC
28.0 (1.7) 2.5 (0.3) 16
ROI VBM
ROI: thalamus and pedunculopontine nucleus;
covariates: age, TIV; group comparisons
Whole brain VBM
Post-hoc analysis; group comparisons
Grey matter volume
ROI VBM
p < 0.05 corrected
PD VH < PD NVH: bilat. PPN
PD/PDD VH < PD NVH: bilat. PPN and thalamus
Whole brain VBM
p < 0.001 uncorrected
PD/PDD VH < PD NVH: PPN and thalamus
DLB/PDD VH < PD VH: R MFC
13 PDD VH 67.7 (7.1) 10.9 (5.5) 21.2 (2.7) 12,14 3.5 (1.0) 12,14
16 PD NVH 64.3 (8.0) 3.1 (3.6) 28.9 (1.6) 15 2.1 (0.5)
11 DLB 62.6 (6.5) 4.6 (4.5) 24.5 (1.4) NA
Kantarci et al.
(2010) [46]
30 DLB 71 (55, 85) 10
NA VH definition;
64% of DLB
27 (14, 34) 10,17
NA
DTI ROI
ROI: cortical GM regions and white matter tracts;
group comparisons
Mean diffusivity
VH > NVH: ILF
30 AD 74 (48, 89) 10 24 (5, 33) 10,17
60 HC 73 (54, 86) 10 36 (28, 38) 10,17
Kantarci et al.
(2012) [19]
21 DLB 73 (60, 87) 10
NA
Freq. of VH: 4
point scale90%
of DLB
22 (6, 29) 10
NA
ROI MRI
Association between freq. of VH and hippocampal
volumes in DLB PET 8
Hippocampal volume
Association with VH freq.: NS21 AD 77 (58, 92)
10 21 (6, 28) 10
42 HC 74 (59, 87) 10 29 (27, 30) 10
Lee et al. (2016)
[20]
10 PD VH 69.2 (5.2) 2 7.2 (3.7) 2
Semi-structured
interview
27.7 (1.6) 2 2.2 (0.5) 2
DTI ROI
ROI: optic nerve, optic radiation bilaterally; group
comparisons
ROI MRI
ROIs: optic chiasm area; LGN volume; V1 volume;
each volume divided by TIV; group comparison
White matter integrity
p < 0.016 corrected
VH < HC: FA: L optic nerve FA
NVH < HC: MD: bilat. optic nerve
VH > NVH and HC: MD: L optic radiation
VH > NVH: axial diffusivity: R optic nerve
VH > HC: RD: L optic radiation
Grey matter volume
VH < NVH: volume: L LGN
VH < HC: volume: bilat. LGN
14 PD NVH 66.1 (6.1) 7.3 (3.7) 28.4 (1.4) 2.1 (0.5)
15 HC 68.5 (6.6) - NA -
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Lee et al. (2017)
[21]
10 PD VH 69.4 (5.3) 2 7.2 (3.7) 2
Based on
consensus
criteria during
clinical
follow-up
27.6 (1.8) 2.2 (0.3) 12,14,16
Whole brain VBM
Covariates: age, gender, TIV; group comparisons;
TBSS DTI
Group comparisons; covariates: age, gender
Grey matter volume
p < 0.001 uncorrected
PD VH < PD NVH: R IPL, and SG
White matter
p < 0.05 corrected
PD VH vs. PD NVH: FA: NS
PD VH < HC: FA: fronto-temporo-parietal and brainstem
regions bilaterally
PD NVH < HC: FA: fronto-temporal-parietal areas,
midbrain and pons bilaterally
PD VH > HC: MD: L temporo-parietal, and lateral
geniculate areas
21 PD NVH 66.2 (6.8) 7.0 (4.2) 28.2 (1.4) 1.8 (0.5)
17 PDD VH 71.1 (5.0) 6.2 (3.0) 20.4 (3.7) 12,14 2.8 (0.8)
30 HC 68.6 (6.0) - NA -
Meppelink et al.
(2011) [24]
11 PD VH NA 2 8.0 (4.7)
NPI
NA 2
NA
Whole brain VBM
Group comparisons; covariates: total grey matter
ROI MRI
ROI: L FG
Grey matter volume
Whole brain VBM
p < 0.05 cluster-level corrected
VH vs. NVH: NS
VH < HC: L temporal areas, parietal, occipital, frontal
regions bilaterally
NVH < HC: L occipital, temporal regions, frontal and
parietal regions bilaterally
ROI: FG: NS
13 PD NVH NA 7.9 (2.4) NA
14 HC NA - NA
Pagonabarraga
et al. (2014) [29]
17 PD mVH 64.1 (9) 2 9.8 (7) 2
MDS-UPDRS
87.2 (13) 2, 18 1.9 (0.3) 2 Whole brain VBM
Covariates: age, gender, global grey matter volume;
group comparisons; cluster threshold of 207 voxels
determined through 1000 Monte Carlo simulations
Grey matter volume
p < 0.001 uncorrected
mVH < NVH: R vermis, and precuneus
mVH > NVH: cerebellum, L IFC
29 PD NVH 66.3 (8) 7.3 (4) 90.3 (13) 1.9 (0.4)
16 HC 66.8 (8) - 91.6 (11) -
Pereira et al.
(2013) [42]
6 PD VH 73.7 (5.4) 2 12.9 (5.7) 2
NPI
26.1 (2) 4,9 3.1 (1) 2 ROI MRI
ROI: hippocampal subfields; correlations with
cognitive measures
Grey matter volume
VH vs. NVH: NS
VH and NVH < HC: CA2-3, CA4-DG
VH < HC: subiculum, whole hippocampus
6 PD NVH 73.8 (6.8) 12.8 (6.3) 27.9 (1.4) 2.9 (0.9)
6 HC 73.6 (6.7) - 27.9 (2.1) -
Ramirez-Ruiz et
al. (2007) [30]
18 PD VH
PD matched
with HC
12.6 (5.6) 2 NPI and
structured
questionnaire
27.0 (2.1) 4,9 3.2 (1.0) 9 Whole brain VBM
Covariates: TIV, MMSE, Hamilton, and H&Y scores;
group comparison
Grey matter volume
p < 0.05 cluster-level corrected
VH < NVH: L LG and bilat. SPL
20 PD NVH 10.6 (4.3) 29.1 (1.4) 2.5 (0.7)
21 HC - 29.4 (2.3) -
Sanchez-Castaneda
et al. (2010) [33]
6 DLB VH 70.17 (12.4) 2 32.8 (17.7) 19
NPI and
Burnes
Questionnaire
17.5 (5) 2 2.6 (0.5) 2
ROI VBM
ROI: frontal, occipital, parietal, and temporal areas;
covariates: TIV, disease duration, duration of
dementia; group comparison; correlation analysis
Grey matter volume
p < 0.05 corrected
DLB VH < DLB NVH: R IFG
PDD VH < PDD NVH: L OFC
Correlations with VH sev.
p < 0.05 corrected
DLB: R IFG (r = 0.89), L precuneus (r = 0.95)
PDD: NS
6 DLB NVH 70.6 (7.1) 30 (11.8) 19 21.2 (8.1) 3 (0.7)
8 PDD VH 75.3 (4.9) 40.5 (16.8) 19, 20 21.5 (3.5) 2.8 (0.6)
7 PDD NVH 70.6 (7.1) 66 (24.8) 19 23.5 (4) 2.6 (1)
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Shin et al. (2012)
[25]
46 PD VH 71.3 (5.9) 2 3.3 (3.0) 2
NPI
25.2 (3.0) 2
NA
Whole brain VBM
Group comparison; covariates: age, sex, PD duration,
intracerebral volume, MMSE score
ROI MRI
Manually delineation of the ROI; group comparisons
Grey matter volume
VBM
VH < NVH
p < 0.001 uncorrected
R IFC, L temporal, and thalamic areas
VH < HC
p < 0.05 corrected
Parahippocampal area, insular cortex
ROI
VH < NVH: SI volume
Correlations with SI volume: verbal memory immediate,
and delayed recall, semantic fluency, go/no-go tests
64 PD NVH 70.7 (5.7) 2.8 (3.0) 25.7 (2.9)
Watanabe et al.
(2013) [31]
13 PD VH 66.6 (5.5) 2 10.0 (5.2) 2
UPDRS I
27.9 (1.9) 2 2.9 (0.6)
2
Whole brain VBM
Covariates: TIV, age, sex; group comparison
Grey matter volume
VH < NVH
p < 0.005 uncorrected
Bilat. PFC, PFC, L ventral cingulate cortex, primary
visual cortex, PCC, occipito-temporal regions, R parietal,
temporal, occipital regions
13 PD NVH 63.6 (10.7) 10.0 (4.0) 29.0 (1.5) 2.4 (0.8)
22 HC 63.4 (6.1) - 29.8 (0.4) -
Yao et al. (2016)
[22]
12 PD VH 70 (64, 72.75) 2, 13 9.1 (3.5) 2
PPRS
28.5 (24, 29.75) 2,13 3.1 (0.7) 2
ROI MRI
Volume, and shape of the hippocampus; covariates:
age, MMSE, intracranial volume; group comparison
ROI DTI
MD of the hippocampus; voxel-based MD of the
hippocampus; covariates: age, MMSE; group
comparison
Resting-state fMRI 8
Hippocampal volume and shape: NS
VH > NVH and HC: MD: R hippocampus; voxel-based
MD (p < 0.05 corrected): R posterior hippocampal regions
15 PD NVH 66 (62, 72) 2 7.1 (5.1) 29 (28, 30) 13 2.9 (0.7)
14 HC 63 (62, 68.75) 2 - 29 (28, 29.25) 13 -
Yao et al. (2014)
[17]
12 PD VH 67.6 (7.4) 2 10.0 (3.5) 2
PPRS
27.6 (2.4) 2 3.2 (0.7) 2 Cortical thickness
Covariates: age, MMSE score and
levodopa-equivalent dosage; group comparison
Resting-state fMRI 8
Cortical thickness
p < 0.05 cluster-level corrected
No differences between groups
12 PD NVH 63.4 (7.4) 8.4 (5.1) 28.5 (1.7) 2.8 (0.9)
14 HC 64.1 (4.0) - 29.1 (0.7) -
1 Mean (SD); 2 no significant differences between groups; 3 no significant differences with AD; 4 VH 6= HC; 5 no differences between DLB and AD; 6 no differences between sPD VH
and sPD NVH; 7 sPD VH and NVH 6= ePD; 8 functional neuroimaging is reported in Table A2; 9 VH 6= NVH; 10 median (range); 11 MMSE: VH 6.5 point decline after 2 years follow-up
(higher percentage of loss compared to NVH); 12 PDD 6= PD NVH; 13 median (interquartile range); 14 PDD 6= PD VH; 15 PD NVH 6= DLB; 16 PD VH 6= PD NVH; 17 Short test of Mental
Status; 18 Parkinson’s disease-Cognitive Rating Scale; 19 months; 20 PDD VH 6= DLB VH, DLB NVH, PDD VH. AD: Alzheimer’s disease; bilat.: bilateral; CAF: Clinician Assessment
of Fluctuations; DLB: dementia with Lewy bodies; ed.: education; ePD: early PD; FA: fractional anisotropy ; FAB: Frontal Assessment Battery; FG: fusiform gyrus; freq.: frequency;
H&Y: Hoehn and Yahr stage; HC: healthy controls; IFC: inferior frontal cortex; IFG: inferior frontal gyrus; IPL: inferior parietal lobule; ITG: inferior temporal gyrus; LG: lingual gyrus;
LGN: lateral geniculate nucleus; LPC: lateral parietal cortex; MD: mean diffusivity; MDS: Movement Disorders Society; MF: middle frontal gyrus; MFC: middle frontal cortex; MMSE:
Mini-Mental State Examination; MRI: magnetic resonance imaging; MSA: multiple system atrophy; NA: not available; NPI: Neuropsychiatric Inventory; NPIhall: NPI hallucination score;
NS: not significant; NVH: no VH; OFC: orbitofrontal cortex; PCC: posterior cingulate cortex; PD: Parkinson’s disease; PDD: Parkinson’s disease dementia; PFC: prefrontal cortex; PPN:
pedunculopontine nucleus; PPRS: Parkinson psychosis rating scale; pro-AD: prodromal AD; pro-DLB: prodromal DLB; project.: projecting; RD: radial diffusivity; ROI: region of interest;
SCOPA-PC: Scales for Outcome in Parkinson’s disease Psychiatric Complications; sev.:severity; SFG: superior frontal gyrus; SFS: superior frontal sulcus; SG: supramarginal gyrus; SI:
Substantia innominate; sPD: severe PD; SPG: superior parietal gyrus; SPL: superior parietal lobe; STG: superior temporal gyrus; UPDRS: Unified Parkinson’s Disease Rating Scale; VBM:
voxel-based morphometry; VH: visual hallucinations.
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Table A2. Summary of functional neuroimaging studies of hallucinating patients with LBD. Only main results related to VH are reported.
Study Sample Age 1
Disease
Duration
(years) 1
VH MMSE 1 H&Y Neuroimaging Methods—VH
Main Results:
Neuroimaging and VH
Boecker et al.
(2007) [61]
8 PD VH 72.88 (6.60) 2 11.00 (6.46) 2
NPI
25.75 (1.67) 2 3.31 (0.59) 3 FDG-PET
Whole brain; covariate: UPDRS III; group
comparison
Cerebral glucose metabolism
p < 0.05 corrected
VH < NVH: bilat. IPL, precuneus, L SG, MFG, MTG,
parahippocampal gyrus, LG, R cingulate gyrus13 PD NVH 70.56 (6.96) 8.05 (5.85) 26.82 (1.54) 2.68 (1.54)
Erskine et al.
(2015) [47]
17 DLB 81.5 (5.5)
NA NPI
19.0 (5.1)
NA
Task-based fMRI
fMRI protocol: see Taylor et al. (2012) [23];
ROI: LGN; correlation analysis with NPIhall
fMRI activations
Correlations between NPIhall and BOLD activation in
the LGN: NS
15 AD 82.5 (9.2) 20.8 (4.4)
19 HC 77.6 (7.1) 29.0 (1.2)
Firbank et al.
(2016) [67] 30 DLB 76.4 (6.0) 39.3 (27.9)
7 NPI 21.7 (4.2) NA
FDG-PET
Covariates: CAMCOG, UPDRS-III, disease
duration; voxel-wise correlation with
NPIhall
Cerebral glucose metabolism
p < 0.05 cluster-level corrected
VH sev. and freq. associated with occipital
hypometabolism
Franciotti et al.
(2015) [16]
15 sPD VH 70 (6) 2 11.3 (4.3) 4,5
NPI and
semi-structured
interview
24.3 (2.2) 2 3.0 (0.5) 5
Resting-state fMRI
ICA (30 components), 9 ROIs centred on the
DMN clusters; nuisance factor: age; fALFF
of each ROI; group comparisons
Cortical thickness 6
Functional connectivity of ROIs centred on the DMN
sPD VH > sPD NVH: L SFS – L IPL; LSFS – L IPL;
LSFS – R IPL; L SFS – PCC; R SFS – L IPL; R SFS; R
IPL; R SFS – PCC; L LPC – R LPC; L IPL – R IPL; L
IPL – PCC; R IPL – PCC
sPD VH > ePD NVH
L SFS and L IPL
fALFF
sPD VH > sPD: R SFS, MFG, LPC, IPL; L MFG, IPL
15 sPD NVH 68 (11) 12.0 (4.5) 5 24.7 (1.8) 3.0 (0.6) 5
15 ePD NVH 66 (9) 3.3 (1.8) 26.2 (1.8) 2.1 (0.4)
15 MSA 67 (5) 3.9 (1.8) 25.2 (1.7) 3.2 (0.8)
15 HC 69 (6) - 28.7 (0.7) -
Gasca-Salas et
al. (2016) [62]
9 PD VH 70.7 (3.9) 2 14.7 (5.4) 2
UPDRS I
27 (1.7) 2
NS differences
FDG-PET
Whole brain; covariates: age, ed., group
comparison
Cerebral glucose metabolism
p < 0.05 corrected
VH < NVH: R LG, ITG, precuneus, precentral gyrus,
L postcentral gyrus, bilat. MOG
12 PD NVH 70.8 (3.4) 14.3 (6.3) 25.9 (2.7)
19 HC 70.1 (3.1) - 29.1 (1.2)
Goetz et al.
(2014) [54] 1 PD VH 66 4
African tribesmen,
chimpanzees, people in
civil war uniform,
catholic nuns
Intact cognitive
function NA
fMRI during VH
VH during scan: African tribesmen and
chimpanzees; event-related design;
comparison between hallucination and
non-hallucination
p < 0.001 uncorrected
Increased activations during VH: bilat. ACC, PCC,
insula, R medial frontal gyrus, postcentral gyrus,
thalamus, brainstem
Decreased activations during VH: R LG, FG, IOG,
cingulate, L MFG, R STG
Heitz et al.
(2015) [73]
36 DLB VH 71.7 (10.2) 2
NA
Assessed by expert
neurologists
21.7 (5.6) 2
NA
SPECT
[99mTc]ECD; covariates: age, type of tracer;
voxel-based comparison; association
between cerebral perfusion and sev. of VH
Cerebral perfusion
p < 0.001 uncorrected
VH < NVH: L ACC, orbitofrontal cortex, cuneus
Association with VH sev.: bilat. ACC, R
parahippocampal gyrus, L orbitofrontal cortex, L
cuneus
30 DLB NVH 73.5 (6.9) 23.3 (4.3)
Holroyd and
Wooten (2006)
[48]
3 PD VH 69.7 (8.7) 2
NA Based on definition of
VH
31.7 (2.1) 2,8
NA
Task-based fMRI
Visual task: coloured geometric shapes
moving in random directions; baseline:
stationary crosshair; group comparison
fMRI activations
VH > NVH: bilat. cuneus, LG, FG, and MTG
VH < NVH: primary visual cortex3 PD NVH 66.0 (2.7) 34.3 (2.1) 8
Howard et al.
(1997) [55] 1 DLB VH 74 18
7 Markets, factories, busy
roads, docks; no insight 16 NA
fMRI during VH
VH during scan: pigeons, sparrows,
pheasants; exposure to photic stimulation;
comparison between hallucination, and
hallucination-free state
Hallucination-free activations: V1 and V2 bilaterally
Activations during VH: limited activation in V1 and
V2
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Iizuka and
Kameyama
(2016) [18]
24 DLB 73 (68, 79) 11 2.8 (1.8, 3.2) 11
NPI
23 (20.5, 24) 11
NA
FDG-PET
Voxel-wise; ROI: CIS ratio; SUVR in PCC
and precuneus + cuneus; correlations with
NPIhall
Structural MRI 6
Positive correlation with NPIhall in DLB: CIS ratio
Negative correlation with NPIhall in DLB: SUVR in
precuneus/cuneus24 AD 74 (69, 81) 11 2.3 (1.6, 2.6) 11 23 (21, 24.5) 11
Imamura et al.
(1999) [65]
16 DLB VH 72.5 (4.6) 2 23.1 (13.0) 2,7
NPI
19.5 (3.9)
NA
FDG-PET
66 ROIs; covariate: MMSE
Cerebral metabolic rate of glucose
VH > NVH: R posterior temporal and parietal areas6 DLB NVH 72.8 (5.3) 28.0 (14.4)
7 15.0 (3.0)
16 AD 73.2 (4.6) 22.2 (13.8) 7 19.7 (3.5)
Kantarci et al.
(2012) [19]
21 DLB 73 (60, 87) 9
NA
Freq. of VH: four-point
scale
90% of DLB with VH
22 (6, 29) 9
NA
FDG-PET
Association between FDG uptake and freq.
of VH
Structural MRI 6
Cerebral glucose metabolism
Negative association with VH freq.: occipital FDG
uptake
21 AD 77 (58, 92) 9 21 (6, 28) 9
42 HC 74 (59, 87) 9 29 (27, 30) 9
Kataoka et al.
(2008) [78] 1 PDD VH 72 NA
Well-formed objects,
humans, animals; VH
developed four years
after the onset of
parkinsonians
symptoms
27 10 NA
SPECT during VH
[99mTc]ECD; VH during scan: spider
without delusions
Increased regional cerebral blood flow: L STG, MTG,
IFG, and apex of R temporal lobe
Lefebvre et al.
(2016) [49]
18 PD VH 63.50 (5.94) 2 9.06 (4.11) 2
NPI
Minor VH
28.00 (1.24) 2 2 (2, 2) 2,11
Task-based fMRI
Visual detection task (threshold evaluation):
circular gratings; whole brain analysis;
covariates: HDRS, TMT-B/TMT-A, Stroop
error score
Behavioural results
Visual detection threshold: NS
fMRI activations at visual threshold
p < 0.01 cluster-level corrected
VH > NVH: R cerebellum, occipital cortex, PFC
VH < NVH: L cingulate, temporal, occipital cortices,
caudate nucleus
16 PD NVH 62.69 (4.09) 8.00 (5.74) 28.88 (1.20) 2 (2, 2) 2,11
17 HC 62.76 (4.19) - 28.47 (1.70) -
Lobotesis et al.
(2001) [74]
23 DLB 79.4 (9) 60.7 (32) 7
Detailed psychiatric
history
18 DLB VH
16.0 (6.1)
NA
SPECT
99mTc-HMPAO; ROI: occipital
hypoperfusion; group comparison
Regional cerebral blood flow
VH vs. NVH: NS50 AD 81.6 (7) 83.1 (34) 17.3 (5.5)
20 HC 78.1 (5) - 28.4 (1.5)
Matsui et al.
(2006) [70]
31 PD VH 71.1 (8.0) 2 10.9 (5.1) 3 Clinical evaluation and
information from
patients and caregivers
25.7 (3.2) 2 3.2 (0.4) 2
SPECT
[123I]IMP; group comparison; multivariate
logistic regression analysis with disease
duration and levodopa equivalent dose as
explanatory variables
Brain perfusion
VH < NVH: bilat. IPL, ITG, precuneus gyrus,
occipital cortex
Significant after correcting for disease duration and
levodopa equivalent dose: bilat. precuneus, L IPL, R
occipital cortex
39 PD NVH 69.0 (7.7) 6.7 (5.7) 26.4 (2.8) 3.0 (0.6)
Meppelink et al.
(2009) [51]
9 PD VH 61.2 (8.2) 2 8.1 (5.0) 2
NPI and questionnaire
based on VH
characteristics in PD
26.8 (1) 2
NA
Task-based fMRI
Perceptual recognition task: animals,
well-known objects, and meaningless
objects gradually popping out; covariates:
movement parameters
Behavioural results
VH vs. NVH (both PD groups were slower than HC):
NS; images recognised: VH 76%; NVH 86%
fMRI activations
During pop-out: NS between groups
p < 0.001 cluster-level corrected
Before pop-out: VH < NVH: R SFG, L LG, bilat. FG
14 PD NVH 64.6 (7.8) 8.7 (4.7) 27.4 (1.3)
13 HC 58.5 (7.5) - 27.9 (0.9)
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Miyazawa et al.
(2010) [69]
22 DLB 74.5 (6.9)
NA
Reported by patients
and relatives
10/ in group A, and 4/
in group B
NA
FDG-PET
Two groups: (A) hypermetab. in peri-motor
areas, cerebellum, and basal ganglia; (B)
hypermetab. in none, one, or two regions;
group comparison in VH freq.
Visual hallucinations more frequent in group AGroup A 74.8 (6.44)
2 16.2 (6.95) 2
Group B 76.6 (6.29) 21.0 (5.67)
Nagahama et al.
(2010) [75]
100 DLB 76.7 (6.7)
NA
Semi-structured
interview
Factor 3: hallucination
of person and feeling of
presence
Factor 4: hallucination
of animals, insects and
objects
21.0 (3.9)
NA
DLB patients: Factor analysis, four factors of
psychotic symptoms identified
SPECT
ROIs DLB 6= HC; relationship between
psychotic symptoms factors and regional
cerebral blood flow; covariates: age, sex,
MMSE, UPDRS-III, dysphoria
Regional cerebral blood flow
Areas of hypoperfusion associated to factor 3
compared to the others: bilat. angular gyrus, R SG, L
ventral occipital gyrus
No areas of hypoperfusion associated to factor 4
21 HC 77.2 (4.8) -
Nagano-Saito et
al. (2004) [63]
8 PD VH 67.6 (6.2) 2 8.6 (5.0) 2
NA
28.3 (1.8) 2 3.6 (0.9) 2 FDG-PET
Whole brain; ROI: dorsolateral PFC, primary
visual cortex, occipital association cortex,
primary motor cortex; group comparison
Relative regional cerebral metabolic rate for glucose
p < 0.05 cluster-level corrected
VH > NVH: L SFG
ROI: dorsal PFC
11 PD NVH 66.0 (7.5) 5.1 (3.8) 28.5 (1.7) 3.2 (0.5)
13 HC 66.2 (4.9) - 29.1 (1.0) -
O’Brien et al.
(2005) [77]
15 DLB 73.8 (7) 2.8 (2.1)
NPIhall decreased over
one year
16.5 (4)
NA
SPECT
99mTc-HMPAO; changes after one year;
multiple regression between change in
perfusion and change in NPIhall
Change in perfusion
p < 0.05 cluster-level corrected
DLB/PDD: negative association between
hallucination score and perfusion in L PCC and
precuneus
14 PDD 71.9 (6) 2.9 (2.8) 20.9 (4)
Oishi et al.
(2005) [71]
24 PD VH 69.5 (7.2) 2 11.1 (5.0) 2 Clinical evaluation and
information from
patients and caregivers
25.1 (3.7) 2 3.3 (0.5) 2 SPECT
[123I]IMP; voxel-by-voxel comparison;
covariates: MMSE, duration of disease
Regional cerebral blood flow
p < 0.05 corrected
VH < NVH: R FG
41 PD NVH 68.6 (7.3) 9.1 (5.0) 26.5 (3.1) 3.0 (0.5)
Osaki et al.
(2005) [72]
20 PD 60.0 (11.3) 8.4 (4.2) Structured clinical
assessment
9 PD with VH, 10 PDD
with VH
26.4 (4.1)
NA
SPECT
[123I]IMP; 23 ROIs: frontal, temporal,
parietal, occipital areas, pons; group
comparison
Regional cerebral blood flow
VH vs. NVH: NS10 PDD 61.0 (8.5) 11.6 (4.1) 17.4 (6.3)
Park et al. (2013)
[64]
7 PD VH 71.0 (4.7) 2 5.4 (3.5) 2
NPI
26.1 (1.7) 12 2 .0 (0.0) 2
FDG-PET
Whole brain; group comparison; whole
brain correlation with NPIhall
Cerebral glucose metabolism
p < 0.001 uncorrected VH < NVH: bilat. middle and
inferior temporal cortex, L LG, and L angular gyrus
CI VH < NVH: temporo-parieto-occipital cortices
Negative correlation with NPI hallucinations score:
glucose metabolism in bilat. STG, L FG, L
Heschl’s gyrus
8 PD CI VH 67.8 (6.8) 6.8 (3.1) 21.6 (5.1) 2.2 (0.7)
13 NVH 66.3 (5.0) 5.1 (3.1) 26.9 (1.4) 1.5 (0.8)
Pasquier et al.
(2002) [76]
34 DLB 73.8 (8) 3.3 (2.5)
NPI
26 DLB VH
17.1 (6.7)
NA
SPECT
[99mTc]ECD; ROI: R and L occipital region;
group comparison
Cerebral perfusion
VH < NVH: R occipital region28 AD 76.3 (7.3) 3.4 (2.7) 15.8 (6.5)
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Table A2. Cont.
Study Sample Age 1
Disease
Duration
(years) 1
VH MMSE 1 H&Y Neuroimaging Methods—VH
Main Results:
Neuroimaging and VH
Peraza et al.
(2014) [57]
16 DLB 76.2 (5.7)
NA NPI
24.2 (3.75)
NA
Resting-state fMRI
Covariates: age, sex, grey matter; regression
of sev. and freq. of VH with seeded
significant cluster from dual regression DLB
< HC
Association with NPIhall: L fronto-parietal, and
sensory-motor networks (uncorrected)
No association with temporal resting-state network17 HC 77.3 (4.7) 29.1 (0.83)
Peraza et al.
(2015) [58]
18 DLB 77.2 (6.18)
NA NPI
23.6 (3.9)
NA
Resting-state fMRI
Graph analysis; correlation between NPIhall
and integrated networks measures
No association between integrated network measures
and NPIhall
Correlation with NPIhall: node degree (L postcentral
gyrus, putamen), nodal betweenness centrality (R
intracalcarine cortex and FG)
19 AD 74.7 (8.5) 22.58 (2.9)
17 HC 76.8 (5.7) 29.1 (0.85)
Perneczky et al.
(2008) [66]
14 DLB VH 69.86 (6.76) 2 5.85 (4.88) 2
NPI
19.57 (5.27) 2
NA
FDG-PET
Whole brain; covariate: MMSE, UPDRS III,
group comparison
Relative cerebral metabolic rate of glucose p < 0.001
uncorrected VH < NVH: R temporo-occipital
conjunction, and MFG
7 DLB NVH 68.86 (3.02) 5.71 (2.67) 23.14 (2.55)
16 HC 65 (8) - 30 (0)
Ramirez-Ruiz et
al. (2008) [52]
10 PD VH 73 (1.9) 2 11.1 (1.7) 2
Presence of VHs at least
seven times per week,
NPI
25.8 (0.6) 3,13 3.1 (0.4) 2
Task-based fMRI
One back repetition detection task (face
recognition); group comparison
Behavioural results
VH < NVH: number of correct responses
VH > NVH: false-positive recognition
fMRI activations
p < 0.05 cluster-level corrected
VH < NVH: R IFG (controlling for antipsychotic
intake) and SFG
VH > NVH: R IFG
10 PD NVH 72.5 (1.9) 11 (1.5) 29.4 (0.4) 2.5 (0.2)
10 HC 71.6 (1.6) - 29.9 (0.5) -
Shine et al.
(2015) [59]
10 PD pBPP 69.5 (8) 2 6.9 (4) 2
MDS criteria for VH
Patients with high % of
misperceptions on the
BPP (PD pBPP, based
on a cut score) also
presented VH
26.0 (3) 2,14
NA
Resting-state fMRI
ROI: DAN, DMN, VAN, visual network;
multiple regression analysis between BPP
error scale, strength of mental imagery, and
strength of connectivity within and between
each network
BPP error score and strength of mental imagery
predicted increased connectivity within the VAN and
DMN, and decreased connectivity between the DAN
and VAN, and the VAN and visual network, and
DAN and visual network.
BPP error score predicted increased connectivity
within VAN and DMN, and impaired connectivity
between the VAN and DAN.
Strength of mental imagery was related to degree of
impaired connectivity between the VAN and visual
network
9 PD nBPP 67.1 (7) 4.4 (3) 27.6 (2) 14
10 HC 63.5 (8) - 28.5 (1) 14
Shine et al.
(2015) [53]
21 PD pBPP 69.3 (6) 2 6.0 (3) 2
UPDRS-II, SCOPA-PC
Patients with high % of
misperceptions on the
BPP (PD pBPP, based
on a cut score) also
presented VH
27.2 (2) 2,14 2.2 (1) 2
Task-based fMRI
BPP paradigm during fMRI; ICA, networks
of interest: DMN, DAN, VAN, VIS; activity
during correct stable items; comparison in
BOLD signal between misperceptions and
correct stable images; functional coupling
between networks; group comparisons
Activity during correctly identified stable items:
Increased activity in the VIS, VH vs. NVH: VIS,
DMN, VAN: NS; decreased activity in DAN
Activity during misperceptions: decreased activity in
the DAN
Misperceptions vs. correct stable images in VH:
visual misperception increased activity in VAN,
DMN
Functional coupling between networks during
misperceptions in VH: increase in functional coupling
between DMN and VIS; decreased in functional
coupling between DAN and DMN, and VAN
14 PD nBPP 66.3 (5) 4.7 (4) 28.6 (2) 14 2.1 (1)
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Stebbins et al.
(2004) [50]
12 PD VH 71.08 (6.39) 2 13.92 (4.89) 2
Self-report, NPI, SAPS
26.17 (2.25) 2 3 (2–4) 2,9
Task-based fMRI
Stroboscopic task; kinematic task (apparent
motion); whole brain and SVC; covariate:
MMSE; group comparisons
fMRI activations
Whole brain, p < 0.001 uncorrected
Stroboscopic stimulation:
NVH > VH: L IPL, R cingulate gyrus
VH > NVH: R IFG, R caudate nucleus
Kinematic stimulation:
NVH > VH: R middle temporal/occipital lobe, R
cingulate gyrus, bilat. SG, L IPL
VH > NVH: L SFG
SMV during apparent kinematic stimulation, p < 0.05
corrected
VH < NVH: area V5/MT
12 PD NVH 73.25 (7.58) 11.17 (3.90) 27.96 (2.09) 3 (2–4)
Taylor et al.
(2012) [23]
17 DLB 81.2 (5.6) 45.4 (32.2) 7,15
NPI
18.8 (5.1)
NA
Task-based fMRI
Passively view of simple visual stimuli
(checkboards, pictures of objects, moving
dot fields); block design; whole brain
analysis; ROIs: V5/MT, V1, V2, and V3
combined, ROI in the lateral occipital cortex;
correlation between fMRI beta values in the
ROIs and NPIhall
ASL-MRI
Perfusion; voxel-based analysis; ROI: same
as fMRI analysis, precuneus and superior
lateral occipital region; correlation between
ASL perfusion and NPIhall
fMRI activations
No correlation with NPIhall
Perfusion
Negative association with NPIhall: V4 perfusion
19 HC 77.6 (7.1) - 29.0 (1.2)
Uchiyama et al.
(2015) [68]
11 PD VH 68.3 (1.6) 2 6.2 (1.1) 2
NPI
27.6 (0.6) 2 3.0 (2, 4) 3 FDG-PET
Covariates: age and sex; whole brain
correlation analysis with NPIhall
Glucose cerebral metabolic rate p < 0.001 uncorrected
Negative correlation with NPIhall: metabolism in the
L IPL
42 PD NVH 65.5 (1.0) 6.3 (0.6) 28.2 (0.3) 2.5 (1, 4)
24 HC 68.0 (1.0) - 28.6 (0.3) -
Yao et al. (2016)
[22]
12 PD VH 70 (64, 72.75)2, 11 9.1 (3.5) 2
PPRS
VH duration: 2.4 (1.1)
years
28.5 (24, 29.75)
2, 11 3.1 (0.7) 2 Resting-state fMRI
Seed-based approach: hippocampus FC;
covariates: age, MMSE; correlation between
cognitive tests and mean FC scores in
clusters where FC was different between
VH and NVH (controlling for age and
visual accuracy scores)
Structural MRI and DTI (ROI) 6
Functional connectivity of the hippocampus
p < 0.05 corrected
VH < NVH: R hippocampus: occipital, temporal
regions; L hippocampus: temporal, occipital regions,
and cerebellum
VH > NVH: R hippocampus: frontal and temporal
regions; L hippocampus: frontal and parietal regions
Negative correlation between R hippocampal FC
with R occipital gyrus, and medial temporal lobe and
visuospatial memory performance
15 PD NVH 66 (62, 72) 11 7.1 (5.1) 29 (28, 30) 11 2.9 (0.7)
14 HC 63 (62, 68.75) 11 - 29 (28, 29.25) 11 -
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Yao et al. (2015)
[60]
12 PD VH 67.6 (7.4) 2 10.0 (3.5) 2
PPRS
VH duration: 22.6 (17.3)
months
27.6 (2.4) 2 3.2 (0.7) 2
Resting-state fMRI
ALFF; FC seed-region based on ALFF
analysis (occipital lobe)
ALFF
p < 0.05 corrected
VH < NVH: occipital lobe: LG, cuneus bilaterally
VH > NVH: R cerebellum posterior lobe, MTL,
IPL/STL
Functional connectivity of occipital seed-region
VH > NVH: bilat. IFG, SFG, MFG, medial frontal
gyrus and STL; R STG, caudate/thalamus, dorsal
anterior cingulate cortex/ventral medial PFC
12 PD NVH 63.4 (7.4) 8.4 (5.1) 28.5 (1.7) 2.8 (0.9)
14 HC 64.1 (4.0) - 29.1 (0.7) -
Yao et al. (2014)
[17]
12 PD VH 67.6 (7.4) 2 10.0 (3.5) 2
PPRS
VH duration: 22.6 (17.3)
months
27.6 (2.4) 2 3.2 (0.7) 2
Resting-state fMRI
Covariates: age, MMSE score, and
levodopa-equivalent dosage; ICA (40
components)
FC in the DMN; group comparison;
correlation between VH sev. and FC in the
clusters that differed between PD groups
Cortical thickness 6
Functional connectivity in the DMN
p < 0.05 corrected
VH > NVH: L and R precuneus/ PCC, R superior
middle frontal lobe
No correlation with VH
12 PD NVH 63.4 (7.4) 8.4 (5.1) 28.5 (1.7) 2.8 (0.9)
14 HC 64.1 (4.0) - 29.1 (0.7) -
1 Mean (SD); 2 no significant differences between groups; 3 VH 6= NVH; 4 no differences between sPD VH and sPD NVH; 5 sPD VH and NVH 6= ePD; 6 structural neuroimaging is reported
in Table A1; 7 months; 8 Telephone Interview for Cognitive Status; 9 median (range); 10 one year before the development of VH, while three years after was 23; 11 median (interquartile
range); 12 differences between groups; 13 VH 6= HC; 14 MoCA; 15 duration of dementia. ACC: anterior cingulate cortex; AD: Alzheimer’s disease; ALFF: amplitude of low-frequency
fluctuation; ASL: arterial spin labelling; BOLD: blood-oxygenation level-dependent; BPP: bistable percept paradigm; CAMCOG: Cambridge cognitive examination; ChEI: cholinesterase
inhibitor; CI: cognitive impairment; CIS: cingulate island sign; DAN: dorsal attention network; DLB: dementia with Lewy bodies; DMN: default mode network; DTI: diffusion tensor
imaging; ed.: education; ePD: early PD; fALFF: fractional amplitude of low-frequency fluctuation; FC: functional connectivity; FDG: [18F]-Fluorodeoxyglucose; freq.: frequency; FG:
fusiform gyrus; fMRI: functional MRI; H&Y: Hoehn and Yahr stage; HDRS: Hamilton depression rating scale; hypermetab.: hypermetabolism; ICA: independent component analysis; IFG:
inferior frontal gyrus; IOG: inferior occipital gyrus; IPL: inferior parietal lobule; ITG: inferior temporal gyrus; L: left; LG: lingual gyrus; LGN: lateral geniculate nucleus; LPC: lateral
parietal cortex sPD; MFG: middle frontal gyrus; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; MOG: middle occipital gyrus; MRI: magnetic resonance
imaging; MSA: multiple system atrophy; MTG: middle temporal gyrus; MTL: medial temporal lobe; NA: not available; nBPP; NPI: Neuropsychiatric Inventory; NPIhall: NPI hallucination
score; NS: not significant; NVH: no VH; pBPP: positive bistable percept paradigm; PCC: posterior cingulate cortex; PD: Parkinson’s disease; PDD: Parkinson’s disease dementia; PET:
positron emission tomography; PFC: prefrontal cortex; R: right; ROI: region of interest; sev.: severity; SFS: superior frontal sulcus; SG: supramarginal gyrus; STG: superior temporal gyrus;
STL: superior temporal lobe; SUVR: standardized uptake value ratio; SVC: small volume correction; TMT: trial making test; UPDRS: Unified Parkinson’s Disease Rating Scale; VAN:
ventral attention network; VH: visual hallucinations; VIS: visual network.
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